Ann M. Navar

Cardiology
3450 W Camp Wisdom Rd
Dallas, TX 75237

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 244 publications

Lipoprotein (a) Testing and Changes in Lipid-Lowering Therapy in Patients With ASCVD: Findings From the cvMOBIUS-2 Registry.

Lipoprotein (a) Testing and Changes in Lipid-Lowering Therapy in Patients With ASCVD: Findings From the cvMOBIUS-2 Registry.

Journal: Circulation. Population health and outcomes
Published: August 30, 2026

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.

Journal: Nature reviews. Nephrology
Published: August 06, 2026

Lipid Profile Testing and Interpretation.

Lipid Profile Testing and Interpretation.

Journal: Circulation
Published: July 06, 2026

Disparities in Activation and Use of Patient Portals Among Spanish-Speaking Patients.

Disparities in Activation and Use of Patient Portals Among Spanish-Speaking Patients.

Journal: Applied clinical informatics
Published: July 01, 2026

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal: Circulation
Published: June 22, 2026

Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a).

Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a).

Journal: Journal of the American College of Cardiology
Published: June 15, 2026

Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.

Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.

Journal: Journal of the American Heart Association
Published: May 14, 2026

Trial of the Oral PCSK9 Inhibitor Enlicitide. Reply.

Trial of the Oral PCSK9 Inhibitor Enlicitide. Reply.

Journal: The New England journal of medicine
Published: May 06, 2026

Association Between Discrimination in Health Care and ASCVD Among Middle-Aged and Older Adults in the United States.

Association Between Discrimination in Health Care and ASCVD Among Middle-Aged and Older Adults in the United States.

Journal: Circulation. Population health and outcomes
Published: May 01, 2026

Global prevalence of elevated high-sensitivity C-reactive protein in patients with atherosclerotic cardiovascular disease, with and without chronic kidney disease: findings from the POSEIDON study.

Global prevalence of elevated high-sensitivity C-reactive protein in patients with atherosclerotic cardiovascular disease, with and without chronic kidney disease: findings from the POSEIDON study.

Journal: Atherosclerosis
Published: April 23, 2026

Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults.

Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults.

Journal: Journal of the American College of Cardiology
Published: April 17, 2026

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Journal: Nature medicine
Published: April 17, 2026
Showing 1-12 of 244

Last Updated: 09/26/2026